alkylating agents, antimetabolites, antimicrotubule, topoisomerase
What are our chemotherapy agents? (4)
b
Involves no response from first drug exposure.
a) tumor heterogeneity
b) Undruggable genomic drivers
c) selective therapeutic pressure
d) tumor growth kinetics
doubling time
As the tumor Increases in size; ________ increases.
d
This form of drug resistance results in a smaller fraction of cells getting killed.
a) tumor heterogeneity
b) undruggable genomic drivers
c) selective therapeutic pressure
d) tumor growth kinetics
c
This type of drug resistance results in survival of the fittest.
a) tumor heterogeneity
b) undruggable genomic drivers
c) selective therapeutic pressure
d) tumor growth kinetics
specific for a single agent, MD resistance, mutation of target enzymes
What are the characteristics of acquired resistance in cancer cells? (3)
a
This form of drug resistance results in different genetic components in the tumor.
a) tumor heterogeneity
b) undruggable genomic drivers
c) selective therapeutic pressure
d) tumor growth kinetics
undruggable genomic drivers, tumor growth kinetics, selective therapeutic pressure, tumor heterogeneity
What are the forms of Cancer-Drug resistance? (4)
toxicity that does not overlap
When selecting chemotherapy agents, choose one with ___________ with the other drugs in the combination.
effectiveness in monotherapy
All drugs selected for combination therapy must exhibit what?
efficacy, toxicity, mechanism of interaction, optimum scheduling, avoidance of dose changes
What are the guidelines regarding Chemo-Combination therapy? (5)
anti-EGFR, KRAS, anti-angiogenic
What are our targeted therapeutics? (3)
checkpoint inhibitors
What is our immunotherapy option?
b
Which is cytostatic?
a) Chemotherapy
b) Targeted Therapy
a
Which acts on rapidly dividing cells?
a) Chemotherapy
b) Targeted Therapy
b
Which acts on targets associated with the proliferation of cancer cells?
a) Chemotherapy
b) Targeted Therapy
alkylating agents, platinum analogs
What are the Cell Cycle-Nonspecific Agents? (2)
b,d
Which act on the S-Phase?
a) Vinca alkaloids
b) Antimetabolites
c) Taxanes
d) Topoisomerase inhibitors
a,c
Which act on the M phase?
a) Vinca alkaloids
b) Antimetabolites
c) Taxanes
d) Topoisomerase inhibitors
d
Which act on the G2 phase?
a) Vinca alkaloids
b) Antimetabolites
c) Taxanes
d) Topoisomerase inhibitors
erlotinib, afatinib, osimertinib, gefitinib
What are the EGFR inhibitors? (4)
Sotorasib
What is the KRAS inhibitor?
bevacizumab
What is the VEGF therapy?
cisplatin, carboplatin
What are the alkylating agents? (2)
pemetrexed, gemcitabine
What are the antimetabolites? (2)
paclitaxel, docetaxel
What are the Taxanes? * Antimicrotubule (2)
topotecan, irinotecan, etoposide
What are the Topoisomerase inhibitors? (3)